Isolated presence of antibody to hepatitis B core antigen in injection drug users: do they need to be vaccinated?
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 11317267.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In a study of 497 injection drug users who had isolated presence of antibody to hepatitis B core antigen (anti-HBc) at the time of enrollment, 404 (81%) retained this condition after a mean of 49 months of follow-up, during which time no new hepatitis B surface antigen marker was detected. These findings support the hypothesis that patients with isolated presence of anti-HBc have strong resistance to reinfection and do not need vaccination.
Medical subject headings
- Hepatitis B Antibodies
- Hepatitis B Core Antigens
- Hepatitis B Vaccines
- Substance Abuse, Intravenous